Pancreatic Cancer

Latest News


Changing the administration schedule for Gemzar (gemcitabine) plus Abraxane (nab-paclitaxel) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.

Patients and families face difficult decisions when the prognosis is poor, but communication and an action plan may help.

Pipeline

The latest in cancer prevention, diagnosis, and treatment.